Congrats Ben on the award of the Future Leader Postdoctoral Fellowship

Monash BDI success in Faculty fellowships

Six postdoctoral researchers from the Monash Biomedicine Discovery Institute (BDI) have received fellowships in two separate schemes offered by the Faculty of Medicine, Nursing and Health Sciences (MNHS).

These awards will support outstanding early career researchers at key points in their careers. This opportunity allows them to continue to pursue their chosen research programs in areas as diverse as understanding gene regulation in prostate cancer, identifying the molecular determinants of immune cell recognition and treating antimicrobial resistant infections.

Congratulations to Dr Sue Nang, Dr Gaofeng Ni and Dr Evan Healy on receiving a Faculty Early Career Postdoctoral Fellowship.

The Early Career Postdoctoral Fellowship (formerly Bridging Postdoctoral Fellowship) provides funding to support the career development of final year PhD students and early career researchers while they apply for externally funded fellowships.

The Future Leader Postdoctoral Fellowships (formerly Senior Postdoctoral Fellowships) are targeted at outstanding candidates who have clear potential to be successful in external career fellowship schemes.

Three Future Leader Postdoctoral Fellowships were awarded to Monash BDI’s Dr Anja Knaupp, Dr Benjamin Gully and Dr Natalie Lister.

Original article

Congratulations Julian on the VCA Mid-Career Research Fellowship

More Research To Improve Survival Rates For Cancer

The Andrews Labor Government is helping Victoria’s best and brightest researchers discover new breakthroughs in cancer prevention, treatment and care.

Minister for Health Martin Foley today announced the 21 recipients from the Victorian Cancer Agency’s latest grants round, who will share in more than $10 million in research grants to work on ground-breaking discoveries.

Dr Paul Beavis from Peter MacCallum Cancer Center is investigating a new way to make CAR T-Cell therapy, a breakthrough treatment for blood cancer, also work against solid tumours.

Dr Laura Forrest also from the Peter MacCallum Cancer Center is testing a new screening tool designed to identify the best support for people with genetic risk factors for cancer.

The Victorian Cancer Plan 2020-24 sets an ambitious target of saving 10,000 lives from cancer by 2025.

In Victoria, the five most common cancers are prostate, breast, bowel and lung cancer, and melanoma. Participating in cancer screening and finding cancer early, before any symptoms are noticed gives the best chance of survival.

More than 90 per cent of bowel cancers can be successfully treated if found early. All eligible Victorians aged 50-74 should screen every two years for bowel cancer by completing a free, at-home screening test sent in the mail.

Due to early detection and better treatment, more Victorian women are surviving breast cancer, with the five-year survival rate now at 91 per cent compared to 73 per cent in 1986. Eligible women aged 50-74 are invited to screen for breast cancer every two years.

Cervical cancer is one of the most preventable cancers with regular cervical screening tests for women aged 25-74 and the HPV vaccination.

This funding takes the total investment by the Victorian Cancer Agency to more than $250 million since it was established by the Victorian Government in 2006.

As part of its dedication to cancer research, the Labor Government allocated a further $2.447 million in the 2020/21 State Budget to increase access to clinical trials and teletrials for regional patients.

Mid-Career Research Fellowship (Biomedical Stream)

Dr Julian Vivian – Monash University

Improving Bone Marrow Transplantation Treatment of Leukaemias by Donor/Recipient ‘Mismatching’

Killer-cell receptors are central to immune surveillance, controlling both T cells and Natural Killer cells. Currently, exploiting Killer-cell receptors in the clinic is hampered by our lack of understanding of the extreme diversity of receptor and ligand pairings. I have recently provided a framework to decipher this receptor/ligand code and will apply this to bone marrow transplantation for the treatment of leukaemia. These studies will underpin the development of new strategies for donor/recipient matching and for the prophylaxis and treatment of cytomegalovirus reactivation in transplantation.

Original article

All grant recipients


Congratulations to Martin Davey

Congratulations to our very own Martin Davey, who has just received an Australian Research Council (ARC) Discovery Early Career Researcher Award (DECRA). The DECRA scheme supports research in areas of critical national importance by enabling outstanding Australian and international early career researchers to conduct their research in Australia.

Martin will receive more than $425,000 for his research project titled ‘Defining the basis of unconventional immune cell development’. With this funding, he aims to undertake discovery research to characterise the transcriptional programs that underpin the development of unconventional immune cells.

Unconventional T lymphocytes are a poorly understood component of the immune system but emerge very early in mammalian life. T cells are defined by their expression of a T cell receptor (TCR), however while the majority express diverse ab TCRs (‘conventional’), the remaining cells express either an alternative γδ TCR or a highly constrained ab TCR (‘unconventional’). The study of the developmental origins of human unconventional immune cells is an emerging and important area of basic research and discovery.

“The development of the immune system in early life is now thought to be critical to our response to immune challenges in adulthood, such as microbial infections. I aim to generate new knowledge in this area by using cutting-edge transcriptome analysis and cellular immunophenotyping at the single cell level to examine the seeding of unconventional immune cells,” Martin said.

“This project aims to advance our understanding of immune cell biology and the programs that control them, while significantly strengthening national excellence in unconventional immune cell research and providing innovative methodology,” he said.

Original article

Congratulations to Richard Berry

Our very own Group leader, Richard has been awarded a 5 year Viertel Senior Medical Research Fellowship.  This is richly deserved recognition for his sustained high level contributions to biomedical science.

Richard will receive $1.25 million ($250,000 per year for five years) to support his research into how viruses and tumours escape cellular immunity.

According to Richard, the immune system is uniquely equipped to detect foreign invaders and abnormal cells. However, viral infections and cancer remain extremely prevalent within the human population, where they create significant burden to the health and wellbeing of society due to their remarkable ability to hide from our immune system.

Understanding the process of immune escape has been critical to the recent breakthrough success of cancer immunotherapy. Richard aims to build on this body of work by studying how cancers and a certain group of viruses, known as cytomegaloviruses (CMV) avoid immune recognition.

“I became interested in CMVs because they are a group of widespread and potentially deadly pathogens that are the undisputed masters of immune escape,” said Richard.

CMVs are able to hide, undetected within our bodies because they have evolved an arsenal of ‘immunoevasins’, which are molecules that function to dampen or otherwise subvert our immune system.

“Identifying the mechanisms by which CMV mediates immune escape will lead to the development of novel strategies to boost the ability of the immune system to combat human diseases,” Richard explained.

This year, the Sylvia and Charles Viertel Charitable Foundation* brought together the Viertel funding with additional funds from two other charitable trusts to make a third fellowship, which was awarded to Richard Berry.

“I’m very grateful to the Sylvia and Charles Viertel Charitable Foundation, Cross Family Trust and Frank Alexander Charitable Trust for the opportunity to explore this area of research. With the support of this fellowship, I hope to identify new mechanisms of immune escape and translate this knowledge into innovative therapies that will benefit the human population” Richard said.

“Medical research, and many innovations to advance our community our community, social, economic and health wellbeing, rely on philanthropy. For nearly 25 years, Sylvia and Charles Viertel’s legacy has been honoured through the fellowships and the establishment of an impressive alumni of medical researchers,” said Jodi Kennedy, General Manager of Charitable Trusts and Philanthropy, Equity Trustees.

Professor Peter Leedman, Chairman of the Viertel Foundation’s Medical Advisory Board, revealed that the 2019 applications for the Fellowships were of an extremely high standard.

“Each year we are impressed by the quality of the candidates and the incredible work they are doing in pursuit of new diagnostics, treatments and preventative strategies for some of our most intractable medical problems,” said Professor Leedman.

Two other Australian researchers were announced 2019 Senior Medical Research Fellows: Professor Andrew Steer from Murdoch Children’s Research Institute and Dr Tracy Putoczki from the Walter and Eliza Hall Institute of Medical Research.

This article is based on a media release originally published by Equity Trustees. Read the full media release.

Click the link for more about the Sylvia and Charles Viertel Charitable Foundation.

*The Sylvia and Charles Viertel Charitable Foundation is managed by Equity Trustees in partnership with co-trustees Justice Debra Mullins AO (Chair), Rex Freudenberg and Paul de Silva.

Original article

Biochemistry Fellowships for ECRS including our own Gabby Watson

Two early career researchers (ECRs) from the Monash Biomedicine Discovery Institute (BDI) have received Fellowships from the Australian Society for Biochemistry and Molecular Biology (ASBMB), in recognition of their outstanding work in their field.

Congratulations to Dr Gabby Watson from the Rossjohn lab and Dr Chris Stubenrauch from the Lithgow lab.

Dr Gabby Watson’s postgraduate research utilised structural biology to design and characterise cyclic peptides targeted to an intracellular breast cancer protein, Grb7. This resulted in six publications, many as first-author, including two in the Journal of Medicinal Chemistry.

She is currently investigating the complexities and specificities of ligand recognition by the inhibitory receptor CD96, an emerging target for cancer immunotherapy, with some of this research recently published in Structure.

This ASBMB Fellowship will enable Dr Watson to travel to Vienna, Austria, to present her latest research at the 32nd European Crystallographic Meeting.

“I am honoured to receive an ASBMB Fellowship, and grateful to have the opportunity to discuss our recent discoveries on CD96 ligand recognition with experts in the European crystallographic community,” Dr Watson said.

Original article